risks of semaglutide Semaglutide: What we know about safety and cancer risk Utilizing Semaglutide for Addressing Type-2

Orforglipron is a non-peptide small molecule (under about 1 kDa), whereas semaglutide, liraglutide, and their relatives are peptides several times larger

The HPA axis mainly includes the parvocellular corticotropin-releasing hormone (CRH), argininevasopressin (AVP) neurons of the hypothalamic paraventricular nuclei (PVN), anterior pituitary corticotrophs and adrenal cortisol-producing cells

Article Google Scholar Vujkovic, M

2023 Aug 19;402(10402):613-626

Glp-1 (Glucagon Like Peptide) Single molecule made in the small intestine and colon Causes the pancreas to make insulin when sugar is in the blood stream, in a dose dependent fashion (the more sugar you have, the more GLP-1 tells the pancreas to release insulin) Tells the gastrointestinal tract to slow down digestion Slows down carbohydrate absorption (so your blood sugar doesnt escalate quickly) Curbs appetite Animal studies show GLP-1 may promote regeneration of the beta cells in the pancreas by fighting programmed cell death (apoptosis)